Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis

References

• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia [West of Scotland Coronary Prevention Study Group]. New Engl J Med 1995;333:1301–7
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels [Cholesterol and Recurrent Events Trial investigators]. New Engl J Med 1996;335:1001–9
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. J Am Med Assoc 1998;279:1615–22
   PubMed Web of Science ®Google Scholar
• Anon. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels [The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group]. New Engl J Med 1998;339:1349–57
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR, et al.; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multi-centre randomised controlled trial. Lancet 2003;361:1149–58
   Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New Engl J Med 2004;350: 1495–504
   Google Scholar
• Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459–67
   PubMed Web of Science ®Google Scholar
• Primatesta P, Poulter NR. Lipid concentrations and the use of lipid-lowering drugs: evidence from a national cross sectional survey. Br Med J 2000;321:1322–5
   PubMed Web of Science ®Google Scholar
• EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554–72
   PubMed Web of Science ®Google Scholar
• Brady AJB, Betteridge DJ. Prevalence and risks of undertreatment with statins. Br J Cardiol 2003;10:218–9
   Google Scholar
• Foley KA, Simpson Jr RJ, Crouse 3rd JR, et al. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003;92:79–81
   Google Scholar
• Adult Treatment Panel III. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. J Am Med Assoc 2001;285: 2486–97
   PubMed Web of Science ®Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, et al.; European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10 (Suppl. 1):S2–S78
   Google Scholar
• Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to National Cholesterol Education Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:215–9
   PubMedGoogle Scholar
• Koren MJ, Hunninghake DB, ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol 2004;44:1772–9
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al.; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39
   Google Scholar
• Brady AJB, Norrie J, Ford I. Failure to achieve cholesterol targets with statins in UK general practice – the Performance for Life Study. PCCS Annual Meeting and AGM, 3–4 October 2003. Available from www.pccs.org.uk/AbstractForm.htm [accessed 24 June 2005]
   Google Scholar
• Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002;20:303–28
   Google Scholar
• Jones PH, Davidson MH, Stein EA, et al.; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses [STELLAR* Trial]. Am J Cardiol 2003;92:152–60
   Google Scholar
• Milionis HJ, Gazi IF, Filippatos TD, et al. Starting with rosuvastatin in primary hyperlipidemia – is there more than lipid lowering? Angiology 2005;56:585–92
   PubMed Web of Science ®Google Scholar
• Hobbs FD, Southworth H. Achievement of English National Service Framework lipid-lowering goals: pooled data from recent comparative treatment trials of statins at starting doses. Int J Clin Pract 2005;59:1171–7
   PubMed Web of Science ®Google Scholar
• Stalenhoef AF, Ballantyne CM, Sarti C, et al. A COmparative study with rosuvastatin in subjects with METabolic syndrome: results of the COMET study. Eur Heart J 2005;26:2664–72
   PubMed Web of Science ®Google Scholar
• Schuster H, Barter PJ, Stender S, et al.; Effective Reductions in Cholesterol Using Rosuvastatin Therapy I Study Group. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin TherapY (MERCURY I) study. Am Heart J 2004;147:705–13
   Google Scholar
• Wolffenbuttel BH, Franken AA, Vincent HH, et al. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes – CORALL study. J Intern Med 2005;257:531–9
   PubMed Web of Science ®Google Scholar
• Schuster H, Fox JC. Investigating cardiovascular risk reduction – the rosuvastatin GALAXY programme. Expert Opin Pharmacother 2004;5:1187–200
   PubMed Web of Science ®Google Scholar
• Clearfield M, Kallend D, Palmer M, for the PULSAR study investigators. Efficacy and safety of rosuvastatin 10 mg versus atorvastatin 20 mg; results of the PULSAR study. Atherosclerosis 2005;6(Suppl.):104
   Google Scholar
• Jones PH, Watkins C, Blasetto JW. Statin therapies for elevated lipid levels compared across doses to rosuvastatin (STELLAR): LDL-C goal achievement with new ATP III recommendations. Atherosclerosis 2005;6(Suppl.):110
   Google Scholar
• McKenney JM, Jones PH, Adamczyk MA, et al.; STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003;19:689–98
   Google Scholar
• Middleton A, Fuat A. Achieving lipid goals in real life: the DISCOVERY-UK study. Br J Cardiol 2006:13;72–6
   Web of Science ®Google Scholar
• Binbrek AS, Elis A, Al-Zaibag M, et al. An open-label, randomized, parallel-group, multicenter study comparing rosuvastatin with atorvastatin for the achievement of lipid goals in high-risk patients in clinical practice: the DISCOVERY Alpha study. Curr Ther Res 2006;67:21–43
   Google Scholar
• Bots AFE, Kastelein JJP, on behalf of the DISCOVERY Netherlands investigators. Achieving lipid goals in real life: the Dutch DISCOVERY study. Int J Clin Pract 2005;59:1387–94
   Google Scholar
• Strandberg TE, Feely J, Sigurdsson EL. Twelve-week, multi-center, randomized, open-label comparison of the effects of rosuvastatin 10 mg/day and atorvastatin 10 mg/day in high-risk adults: a DISCOVERY study. Clin Ther 2004;26: 1821–6
   Google Scholar
• Fonseca FAH, Ruiz A, Cardona-Muñoz EG, et al., for the DISCOVERY PENTA investigators. The DISCOVERY PENTA study – a DIrect Statin COmparison of LDL-C Value: an Evaluation of Rosuvastatin therapY compared with atorvastatin. Curr Med Res Opin 2005;21:1307–15
   Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502
   Google Scholar
• Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101–29
   Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88
   PubMed Web of Science ®Google Scholar
• Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomised clinical trials. Stat Med 1991;10:1665–77
   PubMed Web of Science ®Google Scholar
• Hardy RJ, Thompson SG. Detecting and describing heterogeneity in meta-analysis. Stat Med 1998;17:841–56
   PubMed Web of Science ®Google Scholar
• Kendrach MG, Kelly-Freeman M. Approximate equivalent rosuvastatin doses for temporary statin interchange programs. Ann Pharmacother 2004;38:1286–92
   PubMed Web of Science ®Google Scholar
• Brewer Jr HB. Benefit–risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003;92(Suppl.):23–9K
   Google Scholar
• Davidson MH. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opin Drug Saf 2004;3:547–57
   PubMedGoogle Scholar
• Shepherd J, Hunninghake DB, Stein EA, et al. Safety of rosuvastatin. Am J Cardiol 2004;94:882–8
   PubMed Web of Science ®Google Scholar
• McKenney JM. Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am J Health-Syst Pharm 2005;62:1033–47
   PubMed Web of Science ®Google Scholar
• Alsheikh-Ali AA, Ambrose MS, Kuvin JT, et al. The safety of rosuvastatin as used in common clinical practice. Circulation 2005;111:3051–7
   Google Scholar
• Galson SK, FDA. [Letter to Wolfe SM, Public Citizen]. www.fda.gov/cder/drug/infopage/rosuvastatin/crestor_CP.pdf [accessed 18 January 2006]
   Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al., for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New Engl J Med 2005;352:1425–35
   Google Scholar